Skip to main content

Pharma News

 

Clinical courses

 

Clinical courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • As the news about Russian tennis ace Maria Sharapova admitting to take a banned drug meldonium which led to her failing a drug test at the Australian Open in January shook the world, health experts say that the drug commonly given to heart patients can increase oxygen uptake and endurance levels in healthy people.

  • In a development that could lead to new treatment for those who have suffered failed pregnancies, researchers have discovered that a lack of stem cells in the womb lining causes thousands of women to suffer from recurrent miscarriages.

  • Obesity and eating fatty food are significant risk factors for many types of cancer. A new study has revealed that a high-fat diet makes the cells of the intestinal lining in the gut more likely to become cancerous.

  • Common asthma symptoms are associated with increased levels of stress and anxiety in teens, a study has found.A study by Henry Ford Hospital in Detroit city of Michigan state in the US has found in a small study of 38 asthma patients aged 14-17, that their average scores for stress and anxiety levels were higher than those seen in the general population.

  • Baxalta Incorporated announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval of ADYNOVI, an extended circulating half-life recombinant Factor VIII (rFVIII) treatment, for pediatric, adolescent and adult patients with hemophilia A and for use during surgery. Currently licensed in the U.S. as ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] and under regulatory review in Japan, Canada and Switzerland, ADYNOVI is the only rFVIII treatment for hemophilia A developed based on the demonstrated efficacy of ADVATE [Antihemophilic Factor (Recombinant)].

  • BioMarin Pharmaceutical Inc. announced positive 48-week results from its Phase 1/2 pivotal study for cerliponase alfa, a recombinant human tripeptidyl peptidase 1 (rhTPP1) to treat children with CLN2 disease, a form of Batten disease.  CLN2 disease is a rapidly progressing, fatal neurodegenerative disease with no approved treatments, where the majority of affected children lose their ability to walk and talk by approximately six years of age.

    (adsbygoogle = window.adsbygoogle || []).push({});
Subscribe to Pharma News